In this article
MEDVi and Embody can appear together in searches because both market online treatment and their disclosures mention overlapping service partners. Shared partners, however, are not enough to establish that two brands are the same company.
The public documents we reviewed name MEDVi LLC in an FDA letter and Modern Metabolic Medicine Inc. in Embody’s corporate disclosures. This article explains those records without claiming a complete ownership investigation.
The reviewed records name different legal entities: MEDVi LLC and Embody’s Modern Metabolic Medicine Inc. That does not prove there is no corporate connection. Shared clinical or pharmacy partners alone do not establish common ownership.
What to know first
- The FDA warning letter addresses MEDVi LLC dba MEDVi. Embody’s privacy policy and corporate footer identify Modern Metabolic Medicine Inc. These records establish the names used in those particular documents.
- We did not verify a single current all-inclusive MEDVi weight-loss price from the main page captured for this review. Do not import a price from an older advertisement or a sponsored “review” into your budget without checking the exact offer.
- The exact prescriber, pharmacy, and prescription still need individual verification.
The named entities in the records
The FDA warning letter addresses MEDVi LLC dba MEDVi. Embody’s privacy policy and corporate footer identify Modern Metabolic Medicine Inc. These records establish the names used in those particular documents.
A brand name, legal entity, parent company, and beneficial owner are different concepts. The pages reviewed do not provide a complete ownership chart for both businesses. We therefore cannot turn different names into proof that no common control or other relationship exists.
What overlapping partners can mean
MEDVi and Embody materials refer to outside clinical services and pharmacy relationships. A medical-services organization or a dispensing pharmacy can work with multiple consumer brands. That arrangement can explain similar language and processes without proving shared ownership.
Conversely, different support addresses or logos do not prove that businesses are unrelated. Establishing control would require additional corporate records or a clear statement from the entities, beyond a shared partner list.
Your agreement matters more than a visual similarity
Before purchase, identify the legal entity named in the terms, the medical practice providing care, and the pharmacy that will fill the order. Ask which organization is responsible for refunds, clinical records, and treatment follow-up.
Use the exact account or order you have. MEDVi’s general support information and Embody’s published support information are different; do not assume that contacting one will provide access to the other’s patient account. See MEDVi contact details and Embody contact details.
Evaluate each offer on its own terms
The MEDVi review includes the FDA warning letter addressed to MEDVi. That letter should not automatically be attributed to a different legal entity simply because a partner overlaps. The Embody review covers its own public disclosures and evidence limits.
The same approach applies to price, guarantees, and medication. Confirm the exact offer and prescription rather than assuming that similar branding means identical treatment, terms, or results.
Put this question in the wider picture
Our MEDVi review brings together the company, pricing, care, and pharmacy disclosures. For practical account questions, use MEDVi customer service. A review can help you prepare questions, but it cannot access your order or approve a treatment.
Save the provider’s response alongside the actual offer and agreement. A statement about a general program may not describe the product, payment term, or clinician assigned to you. Recheck time-sensitive details before enrolling or renewing.
Sources & research notes
Checked September 21, 2026. Provider pages document the provider’s own statements; they do not independently establish treatment safety or results. This is desk research, not a product test or clinical review.
- FDA: MEDVi warning letter, February 20, 2026Regulatory / public agency · Checked September 21, 2026
- MEDVi: provider, pharmacy, and contact disclosuresProvider-published information · Checked September 21, 2026
- Embody | Personalized GLP-1 Weight Loss CareProvider-published information · Checked September 21, 2026
- Embody: corporate identity in privacy policyProvider-published information · Checked September 21, 2026
Read our methodology · Commercial disclosure · Request a correction